Literature DB >> 21106450

Reliability of recording uterine cancer in death certification in France and age-specific proportions of deaths from cervix and corpus uteri.

Agnès Rogel1, Aurélien Belot, Florence Suzan, Nadine Bossard, Marjorie Boussac, Patrick Arveux, Antoine Buémi, Marc Colonna, Arlette Danzon, Olivier Ganry, Anne-Valérie Guizard, Pascale Grosclaude, Michel Velten, Eric Jougla, Jean Iwaz, Jacques Estève, Laurence Chérié-Challine, Laurent Remontet.   

Abstract

French uterine cancer recordings in death certificates include 60% of "uterine cancer, Not Otherwise Specified (NOS)"; this hampers the estimation of mortalities from cervix and corpus uteri cancers. The aims of this work were to study the reliability of uterine cancer recordings in death certificates using a case matching with cancer registries and estimate age-specific proportions of deaths from cervix and corpus uteri cancers among all uterine cancer deaths by a statistical approach that uses incidence and survival data. Deaths from uterine cancer between 1989 and 2001 were extracted from the French National database of causes of death and case-to-case matched to women diagnosed with uterine cancer between 1989 and 1997 in 8 cancer registries. Registry data were considered as "gold-standard". Among the 1825 matched deaths, cancer registries recorded 830 cervix and 995 corpus uteri cancers. In death certificates, 5% and 40% of "true" cervix cancers were respectively coded "corpus" and "uterus, NOS" and 5% and 59% of "true" corpus cancers respectively coded "cervix" and "uterus, NOS". Miscoding cervix cancers was more frequent at advanced ages at death and in deaths at home or in small urban areas. Miscoding corpus cancers was more frequent in deaths at home or in small urban areas. From the statistical method, the estimated proportion of deaths from cervix cancer among all uterine cancer deaths was higher than 95% in women aged 30-40 years old but declined to 35% in women older than 70 years. The study clarifies the reason for poor encoding of uterus cancer mortality and refines the estimation of mortalities from cervix and corpus uteri cancers allowing future studies on the efficacy of cervical cancer screening.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21106450     DOI: 10.1016/j.canep.2010.10.008

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  4 in total

1.  Factors associated with under-reporting of head and neck squamous cell carcinoma in cause-of-death records: A comparative study of two national databases in France from 2008 to 2012.

Authors:  Caroline Even; Luis Sagaon Teyssier; Yoann Pointreau; Stéphane Temam; Florence Huguet; Lionnel Geoffrois; Michaël Schwarzinger
Journal:  PLoS One       Date:  2021-02-03       Impact factor: 3.240

2.  The Clinical Efficacy of Chemotherapy Combined with Traditional Chinese Medicine in the Treatment of Cervical Cancer and Its Influence on Cellular Immunity, Serum CEA, and TNF-α.

Authors:  Qiannan Zhao; Juanjuan Liu; Sai Wang; Xiuqin Wang; Xiufang Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-07       Impact factor: 2.629

3.  Cancer incidence and mortality trends in France over 1990-2018 for solid tumors: the sex gap is narrowing.

Authors:  G Defossez; Z Uhry; P Delafosse; E Dantony; T d'Almeida; S Plouvier; N Bossard; A M Bouvier; F Molinié; A S Woronoff; M Colonna; P Grosclaude; L Remontet; A Monnereau
Journal:  BMC Cancer       Date:  2021-06-24       Impact factor: 4.430

Review 4.  Development of an expert system as a diagnostic support of cervical cancer in atypical glandular cells, based on fuzzy logics and image interpretation.

Authors:  Karem R Domínguez Hernández; Alberto A Aguilar Lasserre; Rubén Posada Gómez; José A Palet Guzmán; Blanca E González Sánchez
Journal:  Comput Math Methods Med       Date:  2013-04-18       Impact factor: 2.238

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.